Octreotide acetate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for octreotide acetate and what is the scope of freedom to operate?
Octreotide acetate
is the generic ingredient in six branded drugs marketed by Amryt, Fresenius Kabi Usa, Gland Pharma Ltd, Heritage Pharms, Sagent Pharms Inc, Sun Pharm Inds, Teva Pharms Usa, West-ward Pharms Int, Wockhardt Usa, Mylan Institutional, and Novartis, and is included in twenty-three NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.Octreotide acetate has sixty-two patent family members in twenty-five countries.
There are nineteen drug master file entries for octreotide acetate. Nine suppliers are listed for this compound.
Summary for octreotide acetate
International Patents: | 62 |
US Patents: | 10 |
Tradenames: | 6 |
Applicants: | 11 |
NDAs: | 23 |
Drug Master File Entries: | 19 |
Finished Product Suppliers / Packagers: | 9 |
Raw Ingredient (Bulk) Api Vendors: | 53 |
Clinical Trials: | 45 |
Patent Applications: | 7,491 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price trends for octreotide acetate |
What excipients (inactive ingredients) are in octreotide acetate? | octreotide acetate excipients list |
DailyMed Link: | octreotide acetate at DailyMed |
Recent Clinical Trials for octreotide acetate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Columbia University | Phase 1 |
Albert Einstein College of Medicine | Phase 1 |
Debiopharm International SA | Phase 1 |
Pharmacology for octreotide acetate
Drug Class | Somatostatin Analog |
Mechanism of Action | Somatostatin Receptor Agonists |
Medical Subject Heading (MeSH) Categories for octreotide acetate
Anatomical Therapeutic Chemical (ATC) Classes for octreotide acetate
Paragraph IV (Patent) Challenges for OCTREOTIDE ACETATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
SANDOSTATIN | Injection | octreotide acetate | 0.05 mg/mL (base), 0.1 mg/mL (base) and 0.5 mg/mL (base) packaged in 1 mL pre-filled syringes (preservative-free) | 019667 | 1 | 2008-01-17 |
US Patents and Regulatory Information for octreotide acetate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Pharms Usa | OCTREOTIDE ACETATE | octreotide acetate | INJECTABLE;INJECTION | 075957-002 | Oct 3, 2005 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Amryt | MYCAPSSA | octreotide acetate | CAPSULE, DELAYED RELEASE;ORAL | 208232-001 | Jun 26, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Novartis | SANDOSTATIN | octreotide acetate | INJECTABLE;INJECTION | 019667-002 | Oct 21, 1988 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for octreotide acetate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | SANDOSTATIN | octreotide acetate | INJECTABLE;INJECTION | 019667-005 | Jun 12, 1991 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-001 | Nov 25, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-001 | Nov 25, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for octreotide acetate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2017088625 | 医薬組成物および関連する送達方法 (PHARMACEUTICAL COMPOSITION, AND RELATED DELIVERY METHOD) | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2016126830 | ⤷ Try a Trial | |
Japan | 6771528 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.